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ABSTRACT
Introduction: The aim of the study was to
investigate the clinical safety and effectiveness
of starting insulin aspart (aspart) therapy in
people with type 2 diabetes mellitus (T2DM) as
a sub-analysis of the multinational, non-
interventional A1chieve study.
Methods: Insulin-naı¨ve and insulin-
experienced people with T2DM in routine
clinical care starting aspart alone at baseline
and continuing aspart alone, changing to
biphasic insulin aspart 30 (aspart premix) or
adding a basal insulin by study end, were
included. Safety, tolerability, and efficacy were
evaluated over 24 weeks.
Results: Overall, 3,898 people started aspart at
baseline. Of the 3,313 with 24-week data, 1,545
(46.6%) continued with aspart, 1,379 (41.6%)
switched to aspart premix, and 214 (6.5%)
added basal insulin, while the remainder
switched to other regimens. No serious adverse
drug reactions were reported. The proportion of
participants reporting hypoglycemia decreased
from baseline to week 24 in the aspart alone
group (11.2% versus 4.1%, p\0.001) and in the
aspart ? basal insulin group (13.1% versus
7.5%, p = 0.040), and was 3.7% at week 24 in
the aspart premix group. The mean HbA1c
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decreased from baseline to week 24 (aspart:
-2.1 ± 2.0% [-23 ± 22 mmol/mol], aspart
premix: -2.3 ± 1.7% [-25 ± 19 mmol/mol],
aspart ? basal insulin: -2.0 ± 2.1%
[-22 ± 23 mmol/mol]; p\0.001).
Conclusion: Insulin aspart therapy was well
tolerated and was associated with improved
glucose control over 24 weeks in people with
T2DM.
Keywords: A1chieve; Aspart; Basal insulin;
Biphasic insulin aspart; Type 2 diabetes
INTRODUCTION
The progressive nature of type 2 diabetes
mellitus (T2DM) necessitates that medications
are continually optimized to achieve and
maintain recommended or individualized
metabolic goals [1, 2]. In time, insulin therapy
is almost inevitably required as islet B cell
function declines, and with time, insulin
regimens have to be further optimized to
maintain control to target. However, in some
people, overly rigorous intensification of blood
glucose control can impair a person’s health by
leading to increased risk of hypoglycemia [3].
This gives rise to challenges in identifying and
implementing suitable insulin regimens for
individuals in clinical practice.
Information to assist such decision making
can come not only from randomized clinical
trials (RCTs), but also from non-interventional
studies that allow for selection of a larger, more
representative heterogeneous patient
population, also allowing collection of larger
datasets of efficacy, safety, and tolerability
outcomes.
Insulin aspart (aspart) is a rapid-acting meal-
time insulin analogue studied in a number of
RCTs [4, 5]. In several RCTs, meal-time insulin
alone was started in people with T2DM, on
occasion with optimization of therapy by later
addition of a basal insulin [6–8]. It has been
suggested that this is appropriate as the
progression of insulin deficiency in T2DM
follows from an initial insufficiency of
postprandial glucose control [9].
Postprandial hyperglycemia has been
putatively linked to increased risks of
macrovascular disease, diabetic retinopathy, and
decreased myocardial blood volume and
myocardial blood flow [10–13], and studies show
aspart lowers postprandial plasma glucose (PPPG)
levels to a greater extent than unmodified human
insulin [14]. Insulin aspart is also available as a
premix preparation (biphasic insulin aspart) and
can be combined with a basal insulin in a meal-
time ? basal insulin regimen. In the 4T (Treating
to Target in Type 2 diabetes) study, blood glucose
control and hypoglycemia at 3 years were
comparable for basal insulin added to aspart,
aspart added to biphasic insulin aspart, and aspart
added to a basal insulin [7].
The A1chieve study [15] included people
with T2DM on aspart, biphasic insulin aspart
30 (aspart premix), and insulin detemir in 28
countries in routine clinical practice, albeit for a
shorter period of time. The present subgroup
analysis was conducted to investigate the
clinical safety, tolerability, and effectiveness of
aspart therapy in a cohort of insulin-naı¨ve and
insulin-experienced patients starting aspart
alone at baseline and continuing with aspart
alone, switching to aspart premix, or adding a
basal insulin during the study.
MATERIALS AND METHODS
Study Design
A1chieve was a multinational, 24-week, non-
interventional study to assess the safety and
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effectiveness of the insulin analogs, aspart
(NovoRapid, Novo Nordisk, Bagsvaerd,
Denmark), aspart premix (NovoMix, Novo
Nordisk), and detemir (Levemir, Novo
Nordisk), in routine clinical care [15]. The
participating countries were grouped into
seven regions: China, South Asia (Bangladesh,
India, Pakistan), East Asia (Indonesia, Korea,
Malaysia, Philippines, Singapore, Taiwan),
North Africa (Algeria, Morocco, Tunisia,
Libya), Middle East ? Gulf (Egypt, Iran, Jordan,
Turkey, Bahrain, Kuwait, Oman, Qatar, Saudi
Arabia, United Arab Emirates, Yemen), Latin
America (Argentina, Mexico), and Russia. This
sub-analysis was conducted in a cohort of
previously insulin-naı¨ve or insulin-experienced
patients starting aspart therapy at baseline and
then continuing on aspart alone, switching to
aspart premix, or adding a basal insulin, at the
discretion of their physicians, during the
24-week study period.
There were no pre-defined study procedures
and the participating physicians were
responsible for all aspects of the patient care,
including the decision to appropriately modify
therapies. Study insulins were commercially
available and used as per routine clinical
practice. Data for analysis were collected for
pre-study, baseline (insulin day 1), interim visit
(around 12 weeks from baseline), and final visit
(around 24 weeks from baseline). The use of oral
glucose-lowering drugs (OGLDs) was permitted
throughout the study at the physicians’
discretion.
Patients
Any participant who started therapy on aspart
alone in the 4 weeks prior to baseline and
continued using aspart alone, switched to
aspart premix, or added a basal insulin by
study end was eligible for this sub-analysis.
Women who were pregnant, breast-feeding, or
had the intention of becoming pregnant were
not included.
Compliance with ethics
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. All participants provided
signed informed consent and ethics committee
approvals were obtained for each participating
country.
Assessments and Outcomes
The primary outcome measure was the incidence
of serious adverse drug reactions (SADRs),
including major hypoglycemic events.
Secondary outcomes included the number of
serious adverse events (SAEs), and the change in
the proportion of participants that reported
hypoglycemic events during the 4 weeks
preceding baseline and week 24. A
hypoglycemic event was defined as an event
with symptoms of hypoglycemia that resolved
with oral carbohydrate intake, glucagon or
intravenous glucose, or any symptomatic or
asymptomatic event with a plasma glucose level
of 3.1 mmol/l (56 mg/dl). Nocturnal
hypoglycemic events were defined as
individualized symptomatic events consistent
with hypoglycemia, occurring during sleep, after
the evening insulin injection and before getting
up in the morning, and if relevant, before
morning determination of fasting plasma
glucose (FPG) and the morning insulin
injection. Major hypoglycemic events were
defined as events with severe central nervous
system symptoms consistent with hypoglycemia
in which the patient was unable to self-treat and
characterized by either a plasma glucose level of
3.1 mmol/l (56 mg/dl), or reversal of symptoms
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after either food intake, glucagon or intravenous
glucose administration.
Other secondary outcomes included the
change from baseline to week 24 in HbA1c, FPG,
PPPG, systolic blood pressure, body weight, and
lipid profile. Health-related quality of life
(HRQoL) was assessed based on the change in
visual analog scores (VAS) of the EQ-5D
questionnaire [16] from baseline to week 24.
Laboratory measurements were performed
by local laboratories following local
standardization and quality control procedures.
Statistical Analysis
Statistical analyses were performed for the
groups that continued aspart alone, switched
to aspart premix or added a basal insulin during
the study. Continuous and discrete variables
were summarized using descriptive statistics
(mean, SD) and frequency tables (n,%),
respectively. Two-sided tests at a pre-specified
5% significance level were used for all statistical
analyses. The change from baseline to study end
in the proportion of patients reporting at least
one hypoglycemic event was analyzed using
McNemar’s test. The change from baseline to
study end for all other outcomes was analyzed
using Student’s paired t test. All data were
analyzed by Novo Nordisk personnel using
SAS (Version 9.1.3, SAS, Cary, NC, USA).
RESULTS
Baseline Characteristics and Glucose-
Lowering Regimens
A total of 3,898 people with T2DM started
therapy with aspart alone ± OGLDs at baseline,
of whom 3,313 patients had data available by
study end. The remaining 585 patients were
withdrawn due to loss of contact (434 patients),
adverse drug reaction (1 patient), and other
reasons (150 patients). By region, 1,244
participants from China, 1,851 from South
Asia, 494 from East Asia, 70 from North Africa,
197 from Middle East ? Gulf, 19 from Latin
America and 23 from Russia started aspart
alone ± OGLDs at baseline.
The physicians’ main reason for starting
aspart therapy was to improve glycemic
control (92.2% for participants continuing
aspart alone, 96.7% for switchers to aspart
premix and 93.0% for those adding a basal
insulin).
Of the 3,313 completers, 1,545 patients
(46.6%) continued with aspart alone, 1,379
(41.6%) switched to aspart premix, and 214
(6.5%) added basal insulin by week 24. Other
participants switched to detemir (39, 1.2%),
added aspart premix to aspart (86, 2.6%) or
moved to diverse other regimens (50, 1.5%),
and are not discussed further as the number of
patients was too low for statistical significance.
Baseline characteristics for the three groups
analyzed are presented in Table 1.
The majority of participants were on at least
one OGLD at baseline with metformin and
sulfonylureas being the most commonly used
OGLDs in all groups (Table 1). At week 24, the
proportions of patients on 1 OGLD, 2 OGLDs,
and more than 2 OGLDs were 55.5, 41.3, and
3.2%, respectively, in the aspart group; 70.6,
27.0, and 2.5%, respectively, in the aspart
premix group, and 75.8, 17.6, and 6.6%,
respectively, in the aspart ? basal insulin
group.
Insulin Dose and Frequency
of Administration
Insulin doses and administration frequencies
for each group pre-study, at baseline and at
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week 24 are presented in Table 2. The mean
daily ± SD insulin dose by weight at week 24
was 0.43 ± 0.21 U/kg/day in the aspart alone
group, 0.42 ± 0.19 U/kg/day in the aspart
premix group, and 0.72 ± 0.29 U/kg/day in the
aspart ? basal group.
In the aspart alone group at baseline, 51.9%
of participants used it thrice daily, evolving in
those continuing aspart alone to 41.5% twice
daily and 49.7% thrice daily by week 24. In the
group switching to aspart premix, 58.6%
started aspart thrice daily at baseline, while
85.6% were on twice daily aspart premix at
week 24. In the group adding a basal insulin,
72.3% and 80.8% were administering aspart at
least thrice daily at baseline and week 24,
respectively.
SADRs and SAEs
No SADRs were reported in any of the participants
during the study. Four SAEs (upper
gastrointestinal hemorrhage, hepatic coma,
chronic renal failure, and vascular stenosis) were
reported in those continuing aspart alone, two
(pyrexia and herpes zoster) in those changing to
premix, and one (melaena) in those adding a
basal insulin. All SAEs were considered unlikely to
be related to the study drugs.
Hypoglycemia
Data for hypoglycemia in the 4 weeks pre-
baseline and pre-week 24 are presented in
Table 3. A statistically significant decrease in the
Table 1 Demographic and baseline characteristics
Insulin regimen at week 24
Aspart alone Aspart premix Aspart1 basal
n 1,545 1,379 214
Male/female (%) 58.8/41.2 58.0/42.0 51.4/48.6
Age (years) 53.0 (13.3) 54.6 (12.0) 53.4 (13.0)
Body weight (kg) 67.7 (13.0) 70.0 (11.9) 70.0 (15.7)
Body mass index (kg/m2) 25.2 (4.0) 25.7 (3.9) 25.8 (4.9)
Duration of diabetes (years) 7.4 (6.3) 6.5 (5.3) 8.5 (6.7)
Duration on insulin (years) 1.1 (2.7) 0.8 (2.1) 1.8 (3.3)
HbA1c (%/mmol/mol) 9.4 (1.9)/79 (21) 9.6 (1.7)/81 (19) 9.4 (2.0)/79 (22)
Oral glucose-lowering drugs, n (%)
Total n 983 860 91
Metformin 772 (78.5) 640 (74.4) 68 (74.7)
Sulfonylureas 370 (37.6) 270 (31.4) 20 (22.0)
One 604 (61.4) 604 (70.2) 63 (69.2)
Two 340 (34.6) 237 (27.6) 22 (24.2)
[Two 39 (4.0) 19 (2.2) 6 (6.6)
Data are mean (SD), or as stated
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proportion of patients reporting confirmed any-
time hypoglycemia between baseline and week
24 was noted in the aspart alone group (11.2%
versus 4.1%, p\0.001), and the aspart ? basal
insulin group (13.1% versus 7.5%, p = 0.040),
while there was no statistically significant change
in the aspart premix group (5.1% versus 3.7%,
NS). No events of major hypoglycemia were
reported in the 4 weeks preceding week 24 in
any of the groups.
Table 2 Insulin dose and dosing frequency at pre-study, baseline and week 24
Insulin regimen at week 24
Aspart alone Aspart premix Aspart1 basal
Insulin dose (U/day)
n 1,545 1,379 214
Pre-study 33.0 (18.5) 34.8 (16.4) 39.6 (23.6)
Baseline 27.5 (13.5) 30.3 (12.0) 26.3 (14.1)
Week 24 28.0 (13.3) 28.6 (13.1) 49.1 (22.3)
Insulin dose by body weight (U/kg/day)
n 1,468 1,347 199
Pre-study 0.49 (0.28) 0.50 (0.24) 0.57 (0.32)
Baseline 0.42 (0.22) 0.44 (0.18) 0.40 (0.22)
Week 24 0.43 (0.21) 0.42 (0.19) 0.72 (0.29)
Daily dose frequency
Pre-study, n (%) 423 332 125
Once 89 (21.0) 63 (19.0) 39 (31.2)
Twice 201 (47.5) 205 (61.7) 44 (35.2)
Thrice 102 (24.1) 40 (12.0) 22 (17.6)
[Thrice 31 (7.3) 24 (7.2) 20 (16.0)
Baseline, n (%) 1,545 1,378 213
Once 98 (6.3) 59 (4.3) 24 (11.3)
Twice 592 (38.3) 380 (27.6) 19 (8.9)
Thrice 802 (51.9) 807 (58.6) 154 (72.3)
[Thrice 53 (3.4) 132 (9.6) 16 (7.5)
Week 24, n (%) 1,544 1,379 214
Once 94 (6.1) 63 (4.6) 0
Twice 641 (41.5) 1,181 (85.6) 17 (7.9)
Thrice 767 (49.7) 132 (9.6) 24 (11.2)
[Thrice 42 (2.7) 3 (0.2) 173 (80.8)
Data are mean (SD), or as stated
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From baseline to week 24, the proportion of
patients reporting nocturnal hypoglycemia
significantly decreased in the aspart alone
group (5.4% versus 0.6%, p\0.001), and in
the aspart ? basal insulin group (6.1% versus
0.9%, p = 0.005), but not in the aspart premix
group (2.0% versus 1.4%, NS).
Blood Glucose Control
The mean HbA1c level decreased similarly from
baseline to week 24 in all three groups: from
9.4 ± 1.9% (79 ± 21 mmol/mol) to 7.3 ± 1.1%
(56 ± 12 mmol/mol) in the aspart alone group;
from 9.6 ± 1.7% (81 ± 19 mmol/mol) to
7.3 ± 0.9% (56 ± 10 mmol/mol) in the aspart
premix group; and from 9.4 ± 2.0%
(79 ± 22 mmol/mol) to 7.4 ± 1.3%
(57 ± 14 mmol/mol) in the aspart ? basal
insulin group (all p\0.001, Table 4). At week
24, 36.5, 32.1, and 45.0% of participants in
groups ending on aspart alone, aspart premix,
and aspart ? basal insulin had HbA1c levels
\7.0% (\53 mmol/mol) compared to 8.6, 4.8,
and 6.7% at baseline. The mean FPG and post-
breakfast PPPG levels also decreased to a
clinically and statistically significant extent in
all three groups (all p\0.001, Table 4).
Table 3 Hypoglycemia in the 4 weeks before baseline and before week 24
Insulin regimen at week 24
Aspart alone Aspart premix Aspart1 basal
Rate (event/
person-year)
Percent with at
least 1 event (%)
Rate (event/
person-year)
Percent with at
least 1 event (%)
Rate (event/
person-year)
Percent with at
least 1 event (%)
Overall
Baseline 3.82 11.2 1.56 5.1 4.62 13.1
Week 24 1.06 4.1 1.09 3.7 1.76 7.5
p \0.001 0.066 0.040
Major
Baseline 0.43 1.9 0.16 1.1 0.36 1.4
Week 24 0.0 0.0 0.0 0.0 0.0 0.0
p \0.001 0.001 0.083
Minor
Baseline 3.39 10.6 1.40 4.6 4.25 12.6
Week 24 1.06 4.1 1.09 3.7 1.76 7.5
p \0.001 0.235 0.063
Nocturnal
Baseline 1.12 5.4 0.42 2.0 1.15 6.1
Week 24 0.10 0.6 0.26 1.4 0.12 0.9
p \0.001 0.160 0.005
Overall is confirmed or major anytime hypoglycemia
p-value was calculated using McNemar’s test for the proportion of patients experiencing hypoglycemia
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Lipids, Body Weight, and Systolic Blood
Pressure
All measures of the lipid profile (Table 5)
improved to a similar extent in the three
groups, but low ascertainment and thus small
numbers meant that this was not confirmed
statistically in the aspart ? basal insulin group
except for total serum cholesterol.
There was no clinically or statistically
significant change in body weight in the
aspart alone and aspart premix groups, but a
gain of 0.9 ± 3.5 kg by week 24 in the group
adding basal insulin was statistically significant
(p\0.001) (Table 5).
Clinically and statistically significant
decreases in systolic blood pressure levels were
noted in all three groups by 24 weeks (Table 5).
Quality of Life
The mean HRQoL improved from baseline to
week 24 in all three groups as measured by the
EQ-5D VAS score (aspart alone, 64.8 ± 16.7 to
79.2 ± 10.8 points; aspart premix, 61.5 ± 17.6
to 77.1 ± 10.8 points; and aspart ? basal
Table 4 Blood glucose control at baseline and after 24 weeks
Insulin regimen at week 24
Aspart alone Aspart premix Aspart1 basal
HbA1c (%/mmol/mol)
n 1,067 1,119 144
Baseline 9.4 (1.9)/79 (21) 9.6 (1.7)/81 (19) 9.4 (2.0)/79 (22)
Week 24 7.3 (1.1)/56 (12) 7.3 (0.9)/56 (10) 7.4 (1.3)/57 (14)
Change -2.1 (2.0)/-23 (22) -2.3 (1.7)/-25 (19) -2.0 (2.1)/-22 (23)
p \0.001 \0.001 \0.001
FPG (mmol/L)
n 1,308 1,197 156
Baseline 10.6 (3.5) 11.6 (4.2) 10.5 (4.4)
Week 24 7.3 (2.0) 7.7 (2.4) 7.3 (2.8)
Change -3.3 (3.2) -3.9 (3.4) -3.2 (4.7)
p \0.001 \0.001 \0.001
PPPG (mmol/L)
n 991 935 116
Baseline 15.2 (4.7) 16.5 (5.3) 14.5 (4.8)
Week 24 10.0 (3.1) 11.0 (3.7) 9.6 (3.3)
Change -5.2 (4.5) -5.5 (4.2) -4.9 (4.9)
p \0.001 \0.001 \0.001
Data are mean (SD), or as stated
FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, PPPG postprandial plasma glucose
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Table 5 Baseline and 24-week data for blood lipids, body weight and systolic blood pressure
Insulin regimen at week 24
Aspart alone Aspart premix Aspart1 basal
Total cholesterol (mmol/l)
n 297 324 62
Baseline 5.1 (1.2) 5.2 (1.4) 5.0 (1.7)
Week 24 4.6 (0.9) 4.7 (1.2) 4.6 (1.0)
Change -0.4 (1.1) -0.6 (1.3) -0.4 (1.4)
p \0.001 \0.001 0.03
Triglycerides (mmol/l)
n 322 327 54
Baseline 1.9 (1.1) 2.0 (1.1) 2.0 (1.3)
Week 24 1.7 (0.7) 1.8 (0.8) 1.9 (0.9)
Change -0.3 (0.9) -0.2 (0.9) -0.2 (1.0)
p \0.001 \0.001 0.21
HDL cholesterol (mmol/l)
n 287 298 50
Baseline 1.2 (0.4) 1.1 (0.3) 1.1 (0.3)
Week 24 1.2 (0.4) 1.2 (0.4) 1.2 (0.3)
Change 0.1 (0.4) 0.1 (0.3) 0.1 (0.2)
p \0.001 0.005 0.057
LDL cholesterol (mmol/l)
n 292 306 51
Baseline 3.0 (1.0) 3.2 (1.0) 2.9 (0.9)
Week 24 2.7 (0.8) 2.9 (1.1) 2.6 (0.9)
Change -0.2 (0.9) -0.4 (1.2) -0.2 (1.0)
p \0.001 \0.001 0.083
Body weight (kg)
n 1,367 1,217 182
Baseline 67.4 (12.8) 70.0 (11.7) 70.1 (16.2)
Week 24 67.6 (12.1) 70.1 (11.2) 71.0 (15.3)
Change 0.1 (2.7) 0.1 (2.6) 0.9 (3.5)
p 0.102 0.312 \0.001
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insulin, 68.4 ± 18.0 to 77.7 ± 12.2 points; all
p\0.001).
DISCUSSION
This sub-analysis confirms the clinical safety
and effectiveness of aspart therapy, whether
administered as prandial insulin alone, as the
premixed analogue biphasic insulin aspart (and
thus including protaminated aspart) or when
combined with a basal insulin in a meal-
time ? basal regimen. While it is uncommon
in global clinical practice to begin any insulin
regimen with meal-time insulin alone, of the
66,726 people enrolled in A1chieve on four
continents, this was the case in 3,898 (5.8%),
with some variation from country to country.
Having begun meal-time aspart, adding a
basal insulin or switching to a biphasic insulin
regimen was common (48%) within 24 weeks
and are accepted methods of therapy
intensification that allow coverage of both
meal-time and basal insulin requirements [17,
18]. However, by study end a substantial
proportion (47%) were still taking aspart
alone, suggesting that these patients were then
in satisfactory glucose control or were reluctant
to further intensify their regimen. Clearly, the
majority of study participants were initially
seen as having a predominantly meal-time
insulin requirement, given the small
proportion of participants who subsequently
added a basal insulin (7%) to the initial aspart
regimen.
Baseline characteristics (age, body weight,
and BMI) were broadly similar across the three
groups, but A1chieve was not a randomized
study, and it cannot be assumed that the
populations were comparable in other ways.
Use of a multiple injection regimen
(aspart ? basal) offers more opportunity for
dose titration, and the higher insulin dose in
this group reflects the high dose in the group on
aspart ? basal insulin in the overall A1chieve
cohort [15]. Such people are often judged as
more insulin deficient, consistent with this
group having modestly longer duration of
diabetes from diagnosis (8.5 years) compared
with those who continued aspart alone
(7.4 years) or changed to aspart premix
(6.5 years). The statistically significant
improvements in HbA1c were consistent with
those reported for the main study and were
Table 5 continued
Insulin regimen at week 24
Aspart alone Aspart premix Aspart1 basal
Systolic blood pressure (mmHg)
n 1,064 1,055 166
Baseline 132.3 (17.1) 138.7 (22.2) 133.0 (18.2)
Week 24 127.9 (14.4) 127.1 (12.0) 126.7 (14.2)
Change -4.3 (15.3) -11.6 (21.5) -6.3 (14.9)
p \0.001 \0.001 \0.001
Data are mean (SD), or as stated
HDL high-density lipoprotein, LDL low-density lipoprotein
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comparable between the three groups at
24 weeks. The FPG and PPPG levels also
improved to clinically large extents in all three
groups (all p\0.001). This is consistent with
the observational INSTIGATE study, where
useful reductions in FPG levels were also
reported from meal-time aspart therapy alone
[19]. Indeed, the improvements in FPG levels
with aspart in routine clinical practice are
better than found in RCTs [20] and, together
with the improvements in systolic blood
pressure, lipid profile and the lack of weight
gain, led us to suggest that starting the insulin
analogues in A1chieve may have also been an
opportunity to improve lifestyle measures [15].
Such changes in lifestyle would be expected to
minimize differences between the insulin
regimens.
Insulin aspart therapy was well tolerated
with no SADRs reported in any group during
the study, consistent with the large body of
clinical experience gained in the past 10 years.
Interestingly, there was a decrease from baseline
to week 24 in the proportion of participants
reporting both confirmed anytime and
nocturnal hypoglycemia in the aspart alone
group and the aspart ? basal group. The
findings are consistent with those from the
main study, from a sub-analysis of use of the
aspart ? basal insulin regimen in older people
[15, 21]. For the aspart premix group, data
interpretation is complicated by a lower
baseline rate of anytime hypoglycemia,
although the 24-week rate is not notably
different from the other two groups; however,
the change was not statistically significant.
While reporting fatigue may have been an
issue, or the state of the population in the
4 weeks to baseline, it is again possible that the
opportunity of starting insulin aspart was used
to enhance lifestyle management, including
avoidance of hypoglycemia.
It is encouraging that HRQoL was found to
rise in all three groups from baseline to
24 weeks. All three groups used multiple
injections, so it seems clear that this did not
subtract significantly from the gains that would
be associated with the marked improvement of
blood glucose control. Gains in HRQoL have
been noted in RCTs even where multiple
injections were used [22]. Again, however, it is
also possible that the circumstance in which the
participants in A1chieve started insulin may
have resulted in other enhancements of clinical
care and that these and the lifestyle changes
combined to enhance life quality. The
statistically significant improvements seen in
the lipid profile in the aspart alone and aspart
premix groups, and in total cholesterol in the
aspart ? basal insulin group may also have
contributed to the improved HRQoL at week 24.
Limitations of the A1chieve study included
the lack of randomization, which may mean
that different results in different populations
merely reflect different clinical habits or
population phenotypes. However, the results
here are strikingly similar among the three
defined study groups, and the changes within
each group sufficiently notable to be of interest
without comparison between groups. As this
was a non-interventional study, non-
standardization of study procedures across
sites and regions may also be a factor. Other
useful information would have been dietary and
exercise changes, circumstances of starting the
insulin analog (e.g., in-patient care, referral to a
specialist), and non-diabetes-related
medications. These, as discussed above, limit
data interpretation. Collection of hypoglycemia
data based on the patient’s recall of
hypoglycemic events may have been
problematic, particularly in regard of baseline,
though if anything the results are seemingly
high for that observational point. However, this
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large, non-interventional study did provide an
opportunity to investigate treatment outcomes
related to the use of different regimens of aspart
therapy in around 3,000 people in routine care
in countries with either a lower resource base or
recent economic evolution.
CONCLUSION
In conclusion, insulin aspart therapy was
observed to be well tolerated and efficacious in
routine clinical practice in people with T2DM,
whether administered as meal-time injections
only, as the biphasic formulation, or in
combination with a basal insulin.
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